What those extra letters mean
CJC-1295 is a lab-made relative of growth hormone-releasing hormone, the signal that tells the pituitary gland to release growth hormone. The pituitary is a small gland below the brain. Ipamorelin acts through a different receptor, a receiving point for the hormone ghrelin.
DAC stands for drug affinity complex. It’s an attachment that binds to albumin, a common blood protein, helping CJC-1295 stay around longer. The early rat experiments explored how that works.
The FDA distinguishes CJC-1295 with and without DAC. They aren’t interchangeable. It found no human studies of the form without DAC. The human studies appear to have used DAC, but the exact form and salt weren’t clear. A name alone doesn’t settle what was tested.
Higher hormones aren’t the whole answer
In small studies of healthy adults, CJC-1295 raised growth hormone and IGF-1, a growth factor that responds to it. That shows an effect on hormones. It doesn’t establish better sleep, more muscle or improved recovery.
A cell experiment on the two receptor systems explored how their signals interact. It wasn’t a trial of the blend in people. We found no controlled human trial of the fixed combination in the evidence covered here.
Safety deserves more than a footnote
The FDA review reports reactions at injection sites, headaches and flushing in the small CJC-1295 studies. FDA identifies faster heart rate and flushing-type reactions as serious adverse events; the review also reports low blood pressure. Those findings don’t tell us how safe repeated use of the pair would be.
The ipamorelin review raises a separate concern: possible immune reactions to clumps or impurities in an injected peptide. It found no safety data for ipamorelin injected under the skin. A different route of administration needs its own evidence.
In the bowel-surgery trial, two people given ipamorelin into a vein died after complications of cancer surgery. FDA couldn’t tell whether ipamorelin played a part, but said the deaths raised safety concerns. They don’t establish the risk of an injection under the skin.
The U.S. entries need careful reading
Neither ingredient is FDA-approved. On FDA’s page current as of April 22, 2026, CJC-1295 and ipamorelin acetate appear among withdrawn nominations. Ipamorelin acetate also appears in Category 2 for 503B outsourcing facilities, which compound under a separate U.S. framework.
Withdrawal isn’t clearance, Category 1 status or approval for compounding. These records don’t establish Australian access either. The comparison puts the other names alongside this pair; the children question explains why sermorelin’s history can’t stand in for it.